Acalabrutinib (Calquence®) is accepted for restricted use within NHSScotland for relapsed/refractory chronic lymphocytic leukaemia

Use as monotherapy is restricted to adults with relapsed/refractory chronic lymphocytic leukaemia who have had at least one previous therapy, in whom chemo-immunotherapy is unsuitable.

Source:

Scottish Medicines Consortium